EIRGEN is a pharmaceutical company focused on Oncology, Metabolic. Key products include RAYALDEE.
EIRGEN's Key Drugs
EIRGEN's core commercial portfolio centers on RAYALDEE, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
EIRGEN's Recent FDA Approvals
New NDA/BLA approvals for EIRGEN over the last two years — novel drugs only, excluding generics and label supplements.
EIRGEN's Therapeutic Areas
EIRGEN's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EIRGEN's Top Competitors
EIRGEN's closest competitors by therapeutic-area and drug-target overlap include Merck, Johnson & Johnson, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EIRGEN Pipeline Snapshot
Active clinical trials for EIRGEN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RAYALDEE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2016-02-10
- Latest
- 2024-12-03
- Applications
- 3